Neogenomics Stock Buy Hold or Sell Recommendation

NEO Stock  USD 9.82  0.58  5.58%   
Considering the 90-day investment horizon and your highly speculative risk level, our recommendation regarding NeoGenomics is 'Strong Sell'. The recommendation algorithm takes into account all of NeoGenomics' available fundamental, technical, and predictive indicators you will find on this site.
  
Check out NeoGenomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
In addition, we conduct extensive research on individual companies such as NeoGenomics and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

Execute NeoGenomics Buy or Sell Advice

The NeoGenomics recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on NeoGenomics. Macroaxis does not own or have any residual interests in NeoGenomics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute NeoGenomics' advice using the current market data and latest reported fundamentals.

Time Horizon

3  Months

Risk Tolerance

I love taking a lot of risk
Execute Advice
Sell NeoGenomicsBuy NeoGenomics
JavaScript chart by amCharts 3.21.15
Strong Sell

Market Performance

Very WeakDetails

Volatility

Somewhat reliableDetails

Hype Condition

Over hypedDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Below AverageDetails

Economic Sensitivity

Almost neglects market trendsDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

FrailDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
For the selected time horizon NeoGenomics has a Mean Deviation of 3.18, Standard Deviation of 4.7 and Variance of 22.09
We provide investment recommendation to complement the last-minute expert consensus on NeoGenomics. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time. To make sure NeoGenomics is not overpriced, please verify all NeoGenomics fundamentals, including its price to sales, book value per share, retained earnings, as well as the relationship between the cash and equivalents and target price . Given that NeoGenomics has a price to earning of 272.37 X, we recommend you to check NeoGenomics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your last-minute risk tolerance and investing horizon.

NeoGenomics Trading Alerts and Improvement Suggestions

NeoGenomics generated a negative expected return over the last 90 days
NeoGenomics has high historical volatility and very poor performance
The company reported the last year's revenue of 660.57 M. Reported Net Loss for the year was (78.73 M) with profit before taxes, overhead, and interest of 290.1 M.
NeoGenomics has a frail financial position based on the latest SEC disclosures
Over 98.0% of the company shares are owned by institutional investors
Latest headline from gurufocus.com: NeoGenomics Inc Announces Participation in Key Investor Conferences

NeoGenomics Returns Distribution Density

The distribution of NeoGenomics' historical returns is an attempt to chart the uncertainty of NeoGenomics' future price movements. The chart of the probability distribution of NeoGenomics daily returns describes the distribution of returns around its average expected value. We use NeoGenomics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of NeoGenomics returns is essential to provide solid investment advice for NeoGenomics.
Mean Return
-0.56
Value At Risk
-6.76
Potential Upside
4.18
Standard Deviation
4.70
   Return Density   
JavaScript chart by amCharts 3.21.15-26.43-19.74-13.05-6.69-0.335.511.9718.4324.931.37VARUpside 0.0060.0080.0100.0120.0140.0160.018
JavaScript chart by amCharts 3.21.15GOOGLE
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of NeoGenomics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

NeoGenomics Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument, such as NeoGenomics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading NeoGenomics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2024-12-31
M
American Century Companies Inc2024-12-31
2.9 M
Goldman Sachs Group Inc2024-12-31
2.3 M
Segall Bryant & Hamill2024-12-31
2.1 M
Morgan Stanley - Brokerage Accounts2024-12-31
1.8 M
Loomis, Sayles & Company Lp2024-12-31
1.8 M
Fred Alger Management, Llc2024-12-31
1.7 M
Northern Trust Corp2024-12-31
1.6 M
Emerald Advisers, Llc2024-12-31
1.6 M
Blackrock Inc2024-12-31
20.2 M
Vanguard Group Inc2024-12-31
14.2 M
Note, although NeoGenomics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

NeoGenomics Cash Flow Accounts

202020212022202320242025 (projected)
Change In Cash77.6M66.2M(53.6M)79.3M24.5M16.1M
Free Cash Flow(27.6M)(90.9M)(96.9M)(30.7M)(34.0M)(32.3M)
Depreciation35.7M53.4M69.4M72.6M72.5M76.2M
Other Non Cash Items12.2M13.6M32.0M14.3M(20.2M)(19.2M)
Capital Expenditures29.1M64.1M30.9M28.8M41.1M43.1M
Net Income4.2M(8.3M)(144.3M)(88.0M)(78.7M)(74.8M)
End Period Cash Flow250.6M316.8M263.2M342.5M367.0M385.4M
Change To Inventory(15.2M)1.6M(1.1M)(454K)(2.7M)(2.6M)
Change Receivables(17.3M)(12.6M)(4.7M)(7.6M)(6.8M)(7.2M)
Net Borrowings(5.3M)96.9M331.4M(758K)(871.7K)(828.1K)
Change To Netincome11.0M13.1M(69.9M)27.9M25.1M26.4M
Investments(93.3M)(133.8M)517K76.7M12.9M13.5M

NeoGenomics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to NeoGenomics or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that NeoGenomics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a NeoGenomics stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
-0.58
β
Beta against Dow Jones-0.39
σ
Overall volatility
4.77
Ir
Information ratio -0.12

NeoGenomics Volatility Alert

NeoGenomics exhibits very low volatility with skewness of -1.81 and kurtosis of 5.66. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure NeoGenomics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact NeoGenomics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

NeoGenomics Fundamentals Vs Peers

Comparing NeoGenomics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze NeoGenomics' direct or indirect competition across all of the common fundamentals between NeoGenomics and the related equities. This way, we can detect undervalued stocks with similar characteristics as NeoGenomics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of NeoGenomics' fundamental indicators could also be used in its relative valuation, which is a method of valuing NeoGenomics by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare NeoGenomics to competition
FundamentalsNeoGenomicsPeer Average
Return On Equity-0.0854-0.31
Return On Asset-0.027-0.14
Profit Margin(0.12) %(1.27) %
Operating Margin(0.09) %(5.51) %
Current Valuation1.48 B16.62 B
Shares Outstanding128.46 M571.82 M
Shares Owned By Insiders1.27 %10.09 %
Shares Owned By Institutions98.07 %39.21 %
Number Of Shares Shorted3.43 M4.71 M
Price To Earning272.37 X28.72 X
Price To Book1.40 X9.51 X
Price To Sales1.94 X11.42 X
Revenue660.57 M9.43 B
Gross Profit290.1 M27.38 B
EBITDA(1.51 M)3.9 B
Net Income(78.73 M)570.98 M
Cash And Equivalents465.95 M2.7 B
Cash Per Share3.70 X5.01 X
Total Debt605.33 M5.32 B
Debt To Equity0.59 %48.70 %
Current Ratio7.53 X2.16 X
Book Value Per Share7.04 X1.93 K
Cash Flow From Operations7.02 M971.22 M
Short Ratio3.70 X4.00 X
Earnings Per Share(0.62) X3.12 X
Price To Earnings To Growth3.02 X4.89 X
Target Price19.0
Number Of Employees2.2 K18.84 K
Beta1.23-0.15
Market Capitalization1.28 B19.03 B
Total Asset1.64 B29.47 B
Retained Earnings(325.78 M)9.33 B
Working Capital294.78 M1.48 B
Note: Disposition of 57413 shares by Smith Christopher M of NeoGenomics subject to Rule 16b-3 [view details]

NeoGenomics Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as NeoGenomics . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About NeoGenomics Buy or Sell Advice

When is the right time to buy or sell NeoGenomics? Buying financial instruments such as NeoGenomics Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having NeoGenomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Health Care ETFs Thematic Idea Now

Health Care ETFs
Health Care ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Health Care ETFs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Care ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:
Check out NeoGenomics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.306
Earnings Share
(0.62)
Revenue Per Share
5.215
Quarterly Revenue Growth
0.106
Return On Assets
(0.03)
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

GH
Guardant Health
42.55  0.44  1.04 
CRL
Charles River Labora
165.31  0.43  0.26 
BDSX
Biodesix
0.79  -0.02  -2.47 
CDNA
Caredx Inc
22.15  1.09  5.18 
MYGN
Myriad Genetics
10.73  -0.33  -2.98 
TWST
Twist Bioscience Corp
38.82  0.26  0.67 
MTD
Mettler Toledo Inter
1,273  19.42  1.55 
IQV
IQVIA Holdings
188.80  2.30  1.23 
NTRA
Natera Inc
155.59  -1.02  -0.65 
ACRS
Aclaris Therapeutics
1.99  0.04  2.05 
QGEN
Qiagen NV
38.40  -0.75  -1.92 
NEOG
Neogen
10.05  -0.03  -0.3 
SHC
Sotera Health
12.47  0.19  1.55 
CSTL
Castle Biosciences
21.68  -3.6  -14.24 
OLK
Olink Holding AB
0.00  0.00  0.00 
ICLR
ICON PLC
190.02  0.39  0.21 
SYNH
Syneos Health
0.00  0.00  0.00